Pre- and Post-treatment Levels of Plasma Metabolites in Patients With Bipolar Depression

• Published in: Frontiers in psychiatry Vol. 12; p. 747595
• Main Authors: Guo, Xiang-Jie, Wu, Peng, Cui, Xiao-Hong, Jia, Jiao, Bao, Shuang, Yu, Fei, Ma, Li-Na, Cao, Xiang-Xin, Ren, Yan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 17.12.2021
• Subjects: biomarker; bipolar depression; bipolar disorder (BD); efficacy evaluation; metabolomics; pre- and post-treatment; Psychiatry; bipolar depression; biomarker; bipolar disorder (BD); metabolomics; pre- and post-treatment; efficacy evaluation
• ISSN: 1664-0640; 1664-0640
• DOI: 10.3389/fpsyt.2021.747595

Bipolar disorder (BD) is a serious mental disease with complex clinical manifestations and high recurrence rate. The purpose of this study was to detect metabolites related to the diagnosis and efficacy evaluation of bipolar depression in plasma samples by metabolomics. Thirty-one bipolar depression patients were recruited and completed 8 weeks medication and a matched group of 47 healthy controls (HCs) was recruited. Nuclear magnetic resonance spectroscopy was used to profile plasma samples of bipolar depression patients at baseline and after 8 weeks medication, and HCs. Then Multivariate statistical analysis was performed to analyze differences of plasma metabolites among the three groups. We detected seven specific differential metabolites in bipolar depression. Six of the metabolites were returned to the normal levels in different degrees after 8 weeks medication, only Glycine continuously decreased in the acute and significant improvement stages of bipolar depression (VIP > 1 and < 0.05). These differential metabolites involved several metabolic pathways. The small sample size was one of the most prominent limitations. Each BD patient was given an individualized medication regimen according to the clinical guidelines. There were metabolites changes before and after 8 weeks medication. Glycine may be a characteristic marker of bipolar depression and does not change with the improvement of bipolar depression, while other 6 differential metabolites may be biomarkers associated with the pathological development or the improvement of bipolar depression. And, these differential metabolites mainly related to energy metabolism, amino acid metabolism and gut microbiota metabolism.